3.40
price up icon10.39%   0.32
after-market アフターアワーズ: 3.40
loading
前日終値:
$3.08
開ける:
$3.21
24時間の取引高:
651.24K
Relative Volume:
0.83
時価総額:
$143.54M
収益:
$20.72M
当期純損益:
$-100.84M
株価収益率:
-1.2782
EPS:
-2.66
ネットキャッシュフロー:
$-78.56M
1週間 パフォーマンス:
+9.68%
1か月 パフォーマンス:
-13.27%
6か月 パフォーマンス:
-58.84%
1年 パフォーマンス:
-87.12%
1日の値動き範囲:
Value
$3.11
$3.47
1週間の範囲:
Value
$2.88
$3.47
52週間の値動き範囲:
Value
$2.235
$28.93

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name
名前
4 D Molecular Therapeutics Inc
Name
セクター
Healthcare (1153)
Name
電話
(510) 505-2680
Name
住所
5858 HORTON STREET #455, EMERYVILLE
Name
職員
227
Name
Twitter
Name
次回の収益日
2024-12-13
Name
最新のSEC提出書
Name
FDMT's Discussions on Twitter

FDMT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FDMT
4 D Molecular Therapeutics Inc
3.40 143.54M 20.72M -100.84M -78.56M -2.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-13 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-11-21 開始されました Morgan Stanley Underweight
2024-09-23 ダウングレード Cantor Fitzgerald Overweight → Neutral
2024-04-15 開始されました Barclays Overweight
2024-02-07 再開されました Goldman Buy
2023-10-26 開始されました RBC Capital Mkts Outperform
2023-10-24 開始されました Cantor Fitzgerald Overweight
2023-10-18 アップグレード Leerink Partners Market Perform → Outperform
2023-07-05 開始されました Chardan Capital Markets Buy
2023-01-30 開始されました BMO Capital Markets Outperform
2022-11-18 開始されました H.C. Wainwright Buy
2022-11-15 アップグレード Goldman Neutral → Buy
2022-08-12 ダウングレード SVB Leerink Outperform → Mkt Perform
2022-06-22 開始されました Jefferies Buy
2022-01-04 開始されました SVB Leerink Outperform
2021-01-05 開始されました BofA Securities Buy
2021-01-05 開始されました Evercore ISI Outperform
2021-01-05 開始されました Goldman Neutral
すべてを表示

4 D Molecular Therapeutics Inc (FDMT) 最新ニュース

pulisher
07:20 AM

Discover Fractyl Health And 2 More Promising Penny Stocks - simplywall.st

07:20 AM
pulisher
Apr 21, 2025

Analyzing 4D Molecular Therapeutics (NASDAQ:FDMT) & Gilead Sciences (NASDAQ:GILD) - Defense World

Apr 21, 2025
pulisher
Apr 20, 2025

JPMorgan Chase & Co. Raises Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Apr 20, 2025
pulisher
Apr 18, 2025

What is Leerink Partnrs’ Estimate for FDMT FY2026 Earnings? - Defense World

Apr 18, 2025
pulisher
Apr 18, 2025

Vanguard Group Inc. Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Apr 18, 2025
pulisher
Apr 15, 2025

Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com

Apr 15, 2025
pulisher
Apr 15, 2025

Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com

Apr 15, 2025
pulisher
Apr 15, 2025

American Century Companies Inc. Acquires 4,429 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Wellington Management Group LLP Purchases 11,089 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

8,600 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Acquired by KLP Kapitalforvaltning AS - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

4DMT Announces New Employment Inducement Grants - GlobeNewswire

Apr 11, 2025
pulisher
Apr 10, 2025

4D Molecular Therapeutics, Inc. (FDMT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - ACCESS Newswire

Apr 10, 2025
pulisher
Apr 09, 2025

Weiss Ratings Reaffirms Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Apr 09, 2025
pulisher
Apr 07, 2025

Raymond James Financial Inc. Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Apr 07, 2025
pulisher
Mar 31, 2025

4D Molecular Therapeutics stock hits 52-week low at $3.46 - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

4D Molecular Therapeutics stock hits 52-week low at $3.46 By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 30, 2025

Charles Schwab Investment Management Inc. Sells 29,708 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 30, 2025
pulisher
Mar 27, 2025

PNC Financial Services Group Inc. Raises Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 27, 2025
pulisher
Mar 24, 2025

Here Is How Powerful 4D Molecular Therapeutics Inc (NASDAQ: FDMT) Stock Is - Stocks Register

Mar 24, 2025
pulisher
Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Raises Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 24, 2025
pulisher
Mar 24, 2025

Weiss Ratings Reiterates Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Mar 24, 2025
pulisher
Mar 21, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 15.1% in February - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.63 Average PT from Analysts - The AM Reporter

Mar 20, 2025
pulisher
Mar 20, 2025

Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $30.63 - Defense World

Mar 20, 2025
pulisher
Mar 16, 2025

M&T Bank Corp Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 16, 2025
pulisher
Mar 13, 2025

Proficio Capital Partners LLC Has $111,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

4D Molecular Therapeutics’ SWOT analysis: gene therapy firm faces durability hurdles - Investing.com

Mar 12, 2025
pulisher
Mar 11, 2025

Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News

Mar 11, 2025
pulisher
Mar 11, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $40.00 by Analysts at Bank of America - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy -March 10, 2025 at 09:31 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

4D Molecular Launches Pivotal Phase 3 Trial for Revolutionary Eye Treatment - StockTitan

Mar 10, 2025
pulisher
Mar 09, 2025

Rhumbline Advisers Acquires 3,675 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by New York State Common Retirement Fund - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Analysts Issue Forecasts for FDMT Q1 Earnings - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $28.00 Price Target at Chardan Capital - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.

Mar 04, 2025
pulisher
Mar 04, 2025

Deeper Dive: Understanding 4D Molecular Therapeutics Inc (FDMT) Through its Various Ratios - The Dwinnex

Mar 04, 2025
pulisher
Mar 04, 2025

4D Molecular price target lowered to $35 from $39 at RBC Capital - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

4D Molecular Therapeutics’ (FDMT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank of Canada - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Moderna (NASDAQ:MRNA) and 4D Molecular Therapeutics (NASDAQ:FDMT) Head to Head Review - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

4D Molecular price target lowered to $28 from $30 at Chardan - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics - Benzinga

Mar 03, 2025

4 D Molecular Therapeutics Inc (FDMT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
大文字化:     |  ボリューム (24 時間):